Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 16/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613050 | 0.89 | IKBKB (0.73) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL1385637 | 0.84 | IKBKB (0.65) | IKBKBJAK2CHEK1MAP3K7 | |
| SCHEMBL10051836 | 0.81 | IKBKB (0.68) | IKBKBJAK2JAK3CHEK1 | |
| SCHEMBL1383955 | 0.81 | IKBKB (0.82) | IKBKBCHEK1MAP3K7CYP1A2 | |
| SCHEMBL1382301 | 0.80 | IKBKB (1.00) | IKBKBJAK2JAK3CHEK1CYP1A2 | |
| SCHEMBL4086105 | 0.78 | IKBKB (0.78) | IKBKBJAK2JAK3CHEK1MAP3K7 | |
| SCHEMBL27504382 | 0.77 | MAPT (0.46) | IKBKBJAK2JAK3 | |
| SCHEMBL1382634 | 0.77 | IKBKB (1.00) | IKBKBJAK2JAK3CYP1A2CYP3A4 | |
| SCHEMBL5212019 | 0.77 | IKBKB (0.59) | IKBKB | |
| SCHEMBL1385872 | 0.77 | IKBKB (0.67) | IKBKBJAK2JAK3CHEK1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2009-07-16 | — | — | US | disclosed |
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ABCG2, SULT1E1, TPMT | IKBKB 3065/4885JAK2 79/4885JAK3 436/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | IKBKB 2413/4885JAK2 630/4885JAK3 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.